Veterinary Business Sector

Veterinary business sector encompasses pet care services, animal health products, and veterinary pharmaceuticals, driving market growth with increasing pet ownership and advanced animal healthcare technology. CEOs in this sector focus on strategic leadership, innovation, and operational efficiency to enhance company performance, profitability, and competitive advantage in a rapidly evolving industry.

Zoetis

Kristin Peck, current CEO of Zoetis, has an estimated net worth of approximately $70 million due primarily to her executive compensation, substantial stock awards, and equity holdings in Zoetis.

Merck Animal Health

Rick DeLuca, current CEO of Merck Animal Health, has an estimated net worth of around $30 million primarily due to his executive compensation, stock awards, and long-term incentives from Merck & Co.

Elanco Animal Health

Jeffrey N. Simmons' estimated net worth of around $40 million is primarily derived from his long tenure and executive compensation as CEO of Elanco Animal Health, including salary, bonuses, and substantial holdings of Elanco stock and equity awards.

Boehringer Ingelheim Animal Health

Jean Scheftsik de Szolnok, CEO of Boehringer Ingelheim Animal Health, is estimated to have a net worth of around $5 million based on executive compensation packages, performance bonuses, stock options, and his long tenure in senior management within the pharmaceutical industry.

Bayer Animal Health

Jefferies Graham, current CEO of Bayer Animal Health, has an estimated net worth of around $20 million primarily due to executive salaries, performance bonuses, stock awards, and equity stakes accrued during his leadership roles in biotechnology and pharmaceutical companies.

Ceva Santé Animale

Marc Prikazsky, CEO of Ceva Sante Animale, holds significant equity in the privately held global animal health company, which has driven his estimated net worth to around $30 million due to its strong financial growth and valuation in the veterinary sector.

Virbac

Hugues Bourgeois, current CEO of Virbac, has an estimated net worth of around $5 million primarily from his executive compensation, stock awards, and long-term career in international animal health companies.

Vetoquinol

Matthieu Frechin, CEO of Vetoquinol, has an estimated net worth of around $15 million, primarily accumulating wealth from long-term executive compensation, equity holdings in Vetoquinol, and performance-based bonuses.

Dechra Pharmaceuticals

Ian Page, CEO of Dechra Pharmaceuticals, has accumulated an estimated net worth of around $60 million USD primarily through long-term executive compensation, equity grants, and Dechra's sustained stock price growth since his appointment.

IDEXX Laboratories

Jay Mazelsky's estimated net worth of around $50 million primarily derives from his compensation as CEO of IDEXX Laboratories and substantial holdings of the company's stock.

Phibro Animal Health Corporation

Jack C. Bendheim's estimated net worth of around $500 million primarily stems from his long-term leadership role as CEO and significant shareholding in Phibro Animal Health Corporation, a global animal health and nutrition company.

Nutreco

Fulco van Lede's estimated net worth of around $5 million USD is primarily derived from his executive compensation, bonuses, and stock options accumulated during his tenure as CEO of Nutreco.

Intervet (Now part of Merck Animal Health)

Rick DeLuca's estimated net worth of around $40 million stems from his high-ranking executive roles at Merck Animal Health and other pharmaceutical companies, combined with substantial compensation packages, stock options, and long-term incentives.

Norbrook Laboratories

Huw Hughes, CEO of Norbrook Laboratories, has an estimated net worth of around $2 million, derived from executive compensation, performance bonuses, and equity holdings within the privately-owned pharmaceutical company.

HIPRA

David Nogareda, CEO of HIPRA, has an estimated net worth around $500 million USD due to his significant ownership stake in HIPRA, a leading global biopharmaceutical company specializing in vaccines for animal and human health.

Kyoritsu Seiyaku Corporation

Fumio Tazawa's estimated net worth of around $5 million stems from his executive compensation, equity holdings in Kyoritsu Seiyaku Corporation, and the company's financial performance within the Japanese pharmaceutical sector.

Biochek

Nayha Ohri, current CEO of Biochek, holds significant equity in the company following its recent growth in veterinary diagnostics and multiple investment rounds.

Hester Biosciences

Rajiv Gandhi, current CEO of Hester Biosciences, has an estimated net worth of around $20 million based on his significant equity stake in the company and accumulated executive compensation.

Neogen Corporation

John Adent's estimated net worth of around $25 million is primarily attributed to his executive compensation, stock ownership, and long-term incentive awards accumulated during his tenure as CEO of Neogen Corporation.

Allflex Livestock Intelligence (a division of Merck Animal Health)

Brian Bolton, current CEO of Allflex Livestock Intelligence, is estimated to have a net worth of around $5 million, primarily accumulated through executive compensation, stock options, and leadership roles within Merck Animal Health and its subsidiaries.

MSD Animal Health (Intervet International B.V.)

Rick DeLuca's estimated net worth of around $25 million stems primarily from his executive compensation as president of MSD Animal Health (Intervet International B.V.), which includes salary, stock awards, performance bonuses, and accumulated equity in Merck & Co.

Animana (IDEXX subsidiary)

Gijs van den Heuvel, CEO of Animana (an IDEXX subsidiary), has an estimated net worth of around $1 million USD, primarily derived from his executive compensation, stock options, and leadership role within the veterinary software technology sector.

Covetrus

Benjamin Wolin's estimated net worth of around $30 million derives primarily from his executive compensation, stock holdings, and prior leadership roles at Covetrus and Everyday Health.

MWI Animal Health

Brian Topper, current CEO of MWI Animal Health, has an estimated net worth of around $5 million primarily from executive compensation, stock awards, and performance bonuses granted through his leadership role.

Animalcare Group

Jenny Winter, current CEO of Animalcare Group, has an estimated net worth of around $1 million, primarily derived from her executive salary, performance bonuses, and stock holdings within the company.

Bimeda

Cormac O'Brien, the current CEO of Bimeda, has an estimated net worth of around $15 million, primarily derived from his executive compensation, equity holdings in Bimeda, and performance-based incentives.

Heska Corporation

Kevin S. Wilson, current CEO of Heska Corporation, has an estimated net worth of around $20 million primarily due to his executive compensation, significant stock ownership, and long-term leadership roles within the company.

PetIQ

Cord Christensen's estimated net worth of around $15 million is largely attributed to his executive compensation, stock ownership, and performance-based incentives as CEO of PetIQ, a leading pet health and wellness company.

Genvet

Liu Xiaojun, current CEO of Genvet, has an estimated net worth of around $50 million, driven by his equity stake in the rapidly expanding veterinary pharmaceuticals company and associated profits from its strong market performance in China.

Evonik Industries (Animal Nutrition)

Johannes Kamps, CEO of Evonik Industries' Animal Nutrition business, has an estimated net worth of around $3 million, based on executive compensation, performance bonuses, and accumulated assets tied to his leadership roles at Evonik and previous high-level management positions.

Provimi (Cargill Animal Nutrition)

Adriano Marcon's estimated net worth of around $15 million arises from his executive compensation as CEO of Provimi (Cargill Animal Nutrition), combined with performance-based incentives and long-term equity awards from Cargill, a global leader in food and agribusiness.

Medivet

Chris Cools' estimated net worth of around $3 million reflects his executive compensation, equity holdings, and performance incentives as CEO of Medivet, a leading veterinary care group.

ScanVet

Piotr Leczycki, current CEO of ScanVet, has an estimated net worth of around $2 million, primarily derived from his executive leadership role and equity stake in the company.

O.L. Mix

Stephane Madec, current CEO of O.L. Mix, has an estimated net worth of around $5 million, attributed to his executive compensation, stock options, and leadership roles within the company and related agribusiness ventures.

VetLab Supplies

Lisa Cooper, current CEO of VetLab Supplies, has an estimated net worth of around $3 million, grounded in her ownership stake, executive compensation, and the company's steady revenue from laboratory and veterinary diagnostic equipment.

Zomedica

Larry Heaton, CEO of Zomedica, has an estimated net worth of around $2 million, primarily attributed to his executive compensation, stock ownership, and performance incentives tied to Zomedica's public market valuation.

AniCura

Peter Dahlberg's estimated net worth of around $10 million results from his leadership role as co-founder and CEO of AniCura, a leading European veterinary group acquired by Mars Petcare in 2018 for over $2 billion.

PetMed Express

Matt Hulett's net worth estimation of around $15 million primarily stems from his CEO compensation at PetMed Express, past executive roles at companies like Rosetta Stone and RealNetworks, and equity holdings in public and private tech firms.

Addison Biological Laboratory

Jeffrey S. Boehm, CEO of Addison Biological Laboratory, has an estimated net worth of around $2 million, stemming primarily from his executive salary, ownership of private company shares, and performance bonuses.

VetStem Biopharma

Robert J. Harman's estimated net worth of around $10 million is primarily attributed to his founding role, equity stake, and executive compensation as CEO of VetStem Biopharma, a leading regenerative veterinary medicine company.

Orion Pharma Animal Health

Jari Kivinen's estimated net worth of around $2 million is primarily derived from his executive compensation and stock holdings as CEO of Orion Pharma Animal Health, a subsidiary of the publicly traded Orion Corporation, Helsinki-listed and financially robust.

Recombinetics

Mark Platt, current CEO of Recombinetics, has an estimated net worth of around $5 million due to his executive compensation, equity holdings in the privately held biotech company, and decades of leadership roles in the life sciences industry.

Diamond V (a Cargill company)

Mike Johansen's estimated net worth of around $3 million reflects his executive compensation at Diamond V, a Cargill subsidiary, including salary, performance bonuses, and Cargill stock incentives.